Cargando…

S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA

BACKGROUND: A six-item version (PANSS-6: P1=Delusions, P2=Conceptual disorganization, P3=Hallucinations, N1=Blunted Affect, N4=Social withdrawal, N6=Lack of spontaneity/flow of conversation) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) has shown promise in the measurement of sympto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ostergaard, Soren Dinesen, Foldager, Leslie, Mors, Ole, Bech, Per, Correll, Christoph U
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888357/ http://dx.doi.org/10.1093/schbul/sby018.833

Ejemplares similares

S48. INTER-RATER RELIABILITY OF PANSS-6 SCHIZOPHRENIA SEVERITY RATINGS OBTAINED USING THE SIMPLIFIED NEGATIVE AND POSITIVE SYMPTOMS INTERVIEW (SNAPSI)
por: Kølbæk, Pernille, et al.
Publicado: (2018)

Are informants required to obtain valid ratings on the Positive and Negative Syndrome Scale (PANSS)?
por: Nielsen, Cecilie Marie, et al.
Publicado: (2023)

Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and paliperidone trials
por: Hieronymus, Fredrik, et al.
Publicado: (2023)

Standardized training in the rating of the six-item positive and negative syndrome scale (PANSS-6)
por: Kølbæk, P., et al.
Publicado: (2021)

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
por: Hieronymus, Fredrik, et al.
Publicado: (2021)

M35. CLINICAL VALIDATION OF THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6)
por: Kølbæk, Pernille, et al.
Publicado: (2020)

S244. RELIABILITY OF CORE SCHIZOPHRENIA SYMPTOMS RATINGS USING THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6) PERFORMED BY MEDICAL STUDENTS
por: Hansen, Johanna, et al.
Publicado: (2020)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis
por: Demyttenaere, Koen, et al.
Publicado: (2022)

M210. GRIN2B METHYLATION IS RELATED TO PANSS EXCITED COMPONENT (PANSS-EC) IN SCHIZOPHRENIA
por: Fachim, Helene, et al.
Publicado: (2020)

T109. CLUSTERING OF SCHIZOPHRENIA PATIENT SUBTYPES BY SPECIFIC SYMPTOM DIMENSIONS USING AN UNCORRELATED PANSS SCORE MATRIX (UPSM)
por: Hopkins, Seth, et al.
Publicado: (2018)

Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire
por: Lefort-Besnard, Jérémy, et al.
Publicado: (2018)

Positive and Negative Syndrome Scale (PANSS) predictors of hospitalization during home treatment on 1045 patients with schizophrenia in acute crisis
por: Talisa, R., et al.
Publicado: (2023)

T56. AN EXPLORATORY ANALYSIS CONVERTING SCORES BETWEEN THE PANSS AND BNSS
por: Kott, Alan, et al.
Publicado: (2018)

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2019)

M40. ECT VERSUS SHAM FOR CLOZAPINE RESISTANT SCHIZOPHRENIA: A SECONDARY ANALYSIS OF A PILOT STUDY BASED ON PANSS-30 FACTOR ANALYTIC DIMENSIONS AND THE PANSS-6
por: Luciana Melzer-Ribeiro, Debora, et al.
Publicado: (2020)

Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses
por: Zeller, Scott, et al.
Publicado: (2017)

S49. EFFICACY OF HIGH-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ON PANSS FACTORS IN SCHIZOPHRENIA WITH PREDOMINANT NEGATIVE SYMPTOMS – RESULTS FROM AN EXPLORATORY RE-ANALYSIS
por: Hansbauer, Maximilian, et al.
Publicado: (2018)

Factor analysis of the relationship between PANSS score and family burden of patients with schizophrenia
por: Huang, Jiang, et al.
Publicado: (2021)

The Correlation of Positive and Negative Symptoms (PANSS Scores) in Patients with Schizophrenia According to Gender
por: Sulejmanpasic, Gorana, et al.
Publicado: (2023)

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
por: Davis, Robert, et al.
Publicado: (2018)

Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
por: Krekels, EHJ, et al.
Publicado: (2017)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY
por: Khan, Anzalee, et al.
Publicado: (2018)

Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging
por: Sharafi, Mohammad
Publicado: (2005)

S118. CAN THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) DIFFERENTIATE REFRACTORY FROM NON-REFRACTORY SCHIZOPHRENIA? A FACTOR ANALYTIC INVESTIGATION BASED ON DATA FROM THE PATTERN COHORT STUDY
por: de Freitas, Rosana, et al.
Publicado: (2018)

Is the PANSS used correctly? a systematic review
por: Obermeier, Michael, et al.
Publicado: (2011)

S67. INTEGRATION OF SENSORY AND SOCIAL INFORMATION DURING DECISION MAKING IN SCHIZOPHRENIA
por: Simonsen, Arndis, et al.
Publicado: (2018)

F84. ASSOCIATIONS BETWEEN INTELLIGENCE, VERBAL WORKING MEMORY AND PROCESSING SPEED IN PARENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER AND THEIR 7-YEAR OLD OFFSPRING
por: Greve, Aja, et al.
Publicado: (2018)

Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia
por: Jerrell, Jeanette M., et al.
Publicado: (2013)

Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials
por: Podichetty, Jagdeep T., et al.
Publicado: (2021)

Changes in neurotransmitter levels, brain structural characteristics, and their correlation with PANSS scores in patients with first-episode schizophrenia
por: Xu, Xian-Jia, et al.
Publicado: (2023)

T46. TARGETING THE IMMUNE SYSTEM TO TREAT DEPRESSION AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Krynicki, Carl, et al.
Publicado: (2018)

PM385. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies
por: Correll, Christoph U., et al.
Publicado: (2016)

Neuroticism, depression and anxiety in takotsubo cardiomyopathy
por: Christensen, Thomas Emil, et al.
Publicado: (2016)

S98. THE RELATIONSHIP BETWEEN CARDIOVASCULAR RISK FACTORS AND COGNITIVE IMPAIRMENT IN PEOPLE WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hagi, Katsuhiko, et al.
Publicado: (2018)

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2019)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
por: Kaliuzhna, Mariia, et al.
Publicado: (2020)

T12. THE RELATIONSHIP OF INTESTINAL PERMEABILITY FACTORS WITH SOCIODEMOGRAPHIC AND PHYSICAL HEALTH FACTORS AND PANSS SCORES IN SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS
por: Borkent, Jenny, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7jmgrr7mpp7u2duh3kruvreoo4